文献速递白血病淋巴瘤浆细胞疾病

血液肿瘤治疗进展挽救的生命年:回顾性分析

Life-years saved by advances in blood cancer therapy: a retrospective analysis.
PubMed 文献 · Blood Adv · 2026-01-01

不同年龄和种族间进展不均,除多发性骨髓瘤外,黑人患者生存结局均差于白人。

要点

  • NHL因高发病率贡献大,HL和ALL累积时间最长。
  • AML的LYS最低,MM、CLL和CML居中。

核心结论

  • 不同血液肿瘤类型、年龄和种族间的进展不均衡。

研究设计与样本

  • 回顾性分析,采用生命年挽救(LYS)方法量化美国主要血液肿瘤治疗进展的影响。

主要发现

  • 非霍奇金淋巴瘤因高发病率突出,霍奇金淋巴瘤和急性淋巴细胞白血病累积LYS时间最长。
  • 急性髓系白血病LYS最低,多发性骨髓瘤、慢性淋巴细胞白血病和慢性髓性白血病居中。
  • 除多发性骨髓瘤外,黑人患者所有血液肿瘤生存结局均差于白人患者。

临床怎么用

  • LYS方法可用于评估未满足需求并追踪进展,尤其在进展滞后的领域。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The impact of research and the development of therapeutics for blood cancer must be measured to direct future studies. Here, we used a life-years saved (LYS) methodology to quantify that impact. We estimate 25.8 million cumulative LYS across major blood cancer types in the United States since 1949. Most LYS (∼20 million) were for Hodgkin lymphoma (HL), acute lymphoblastic leukemia (ALL), and non-Hodgkin lymphoma (NHL). NHL stands out due to a high incidence, whereas HL and ALL have accumulated LYS over the longest period. LYS were lowest for acute myeloid leukemia and intermediate for multiple myeloma, chronic lymphocytic leukemia, and chronic myeloid leukemia. Progress has also been uneven across ages and racial groups. Black patients had worse survival outcomes than White patients for all blood cancers except multiple myeloma. The LYS methodology may be used to assess unmet needs and track progress, particularly in areas in which progress lags.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Chang DC, Eisfeld AK, Greenberger LM, et al. Life-years saved by advances in blood cancer therapy: a retrospective analysis. Blood Adv. 2026. PMID: 42678282. doi:10.1182/bloodadvances.2026019813

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。